AbbVie Deal Signals Growing Pharma Interest in Psychedelics
AbbVie's $1.2 billion deal for a depression asset is signaling a major shift, with large pharmaceutical firms now seriously eyeing the psychedelic therapeutics market.
#Psychedelics#Pharmaceuticals#Mental Health